MedTrace Logo

Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

NCT07163845 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5354

Last updated 2026-02-11

No results posted yet for this study

Summary

This is a cross-sectional serosurvey using household cluster sampling conducted before the VLA1553 pilot vaccination strategy will be implemented in about 10 municipalities in Brazil.

Conditions

  • Chikungunya Virus Infection

Interventions

BIOLOGICAL

Live-attenuated CHIKV vaccine VLA1553

Non-interventional study: VLA1553 is used in the pilot vaccination strategy which is carried out after this observational study.

Sponsors & Collaborators

  • Fundação Butantan

    collaborator UNKNOWN

  • Coalition for Epidemic Preparedness Innovations

    collaborator OTHER

  • Valneva Austria GmbH

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-22
Primary Completion
2026-07-31
Completion
2026-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07163845 on ClinicalTrials.gov